Business Wire

CA-BELKIN

Share
Belkin Introduces Future Ventures Division for Further Product Innovation and New Category Creation

Belkin, a leading consumer electronics brand for 40 years, today announced a new division to the company, Future Ventures. This division will focus on opportunities and new avenues for Belkin to explore creative solutions for the modern world including content creation, spatial computing, Artificial Intelligence, robotics, and more. The first two products from this new line are the Auto-Tracking Stand Pro, announced earlier this year at CES 2024, and a new Battery Holder for Apple Vision Pro.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240202187821/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

The first two products from Belkin Future Ventures division are the Auto-Tracking Stand Pro, announced earlier this year at CES 2024, and a new Battery Holder for Apple Vision Pro. (Photo: Business Wire)

Future Ventures will be comprised of forward-thinking designers, engineers and product managers all in-house at Belkin’s headquarters in El Segundo, CA and in satellite hubs worldwide. Belkin’s longstanding legacy in creating quality and human-centric peripheral mobile and computer accessories is the basis behind this new division, and steadily positions the company for new products and categories for the next generation.

“Belkin has been innovating for over 40 years, and Future Ventures was a clear next step in our plans to continue bringing new ideas to the table,” said Steve Malony, CEO, Belkin. “We know that good ideas come from anywhere, so we are looking everywhere to explore new categories and products that we believe in. Future Ventures opens the door to new markets that Belkin has not typically been part of in previous years. We experienced major success at CES 2024 with our new Auto-Tracking Stand Pro, but this is just the beginning of what this new division is capable of.”

The Auto-Tracking Stand Pro

The world’s first Apple certified Works with DockKit accessory, the Auto-Tracking Stand Pro provides seamless hands-free camerawork for content creators, filmmakers, educators, virtual presenters, social app developers, and more. DockKit’s automated subject tracking technology is designed to follow subjects on camera as they move around their space with 360 degrees of pan and 90 degrees of tilt. Additionally, the Auto-Tracking Stand Pro is made more responsibly with a minimum of 75% PCR materials and sold in plastic-free packaging in line with Belkin’s commitment to find more responsible ways to build products.

The Auto-Tracking Stand Pro is $179.99 USD and is available to pre-order on belkin.com. Media kit is available for download HERE.

Battery Holder for Apple Vision Pro

Designed to keep the Apple Vision Pro Battery secure, the Battery Holder allows for a convenient and versatile hands-free experience. The Battery Holder offers a quick and easy way to clip the battery onto a belt or pants, while the cross-body strap gives those without clip access a great way to secure the battery while using Apple Vision Pro.

The Battery Holder is $49.95 USD and is now available at apple.com. Media kit is available for download HERE.

For more information on Belkin’s products, please visit Belkin.com or follow Belkin on Instagram, Facebook, TikTok, LinkedIn and X.

About Belkin

Belkin is a California-based accessories leader delivering award-winning power, protection, productivity, connectivity, and audio products over the last 40 years. Designed and engineered in Southern California and sold in more than 100 countries around the world, Belkin has maintained its steadfast focus on research and development, community, education, sustainability and most importantly, the people it serves. From our humble beginnings in a Southern California garage in 1983, Belkin has become a diverse, global technology company. We remain forever inspired by the planet we live on, and the connection between people and technology.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240202187821/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Kolmar Korea Named One of the TIME’s World’s Best Companies for Sustainable Growth26.12.2024 15:00:00 CET | Press release

Ranks 125th Among 500 Companies Around the GlobeTop 10% in the Environmental Sector Among 3,000 Major Global Companies Kolmar Korea (KRX: 024720) has been recognized by TIME Magazine as one of the World’s Best Companies for Sustainable Growth 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241226863828/en/ Kolmar Korea on TIME's World's Best Companies in Sustainable Growth 2025 (Image: Kolmar Korea) On November 27, TIME, in collaboration with a global market research firm Statista, unveiled a list of the top 500 companies worldwide, demonstrating exceptional sustainable growth. Kolmar Korea took place 125th around the globe and 6th among Korean companies. Notably, it was the only Korean cosmetics company on the list, which featured a total of 23 Korean companies. The rankings were based on an evaluation of revenue growth, financial stability, and environmental impact, each contributing equally to a final score out of 10

Seoul Semiconductor: Philips Lighting Products Ordered to Recall 7-Year-Old Items26.12.2024 08:00:00 CET | Press release

The German District Court of Düsseldorf, on November 19 ruled in favor of Seoul Semiconductor (KOSDAQ:046890) in the patent infringement lawsuits, and also ordered that products manufactured by Philips Lighting and sold since March 2017 be recalled and destroyed. The Court also ruled that a fine of up to €250,000 would be imposed for each violation of this order. On December 17, the German Federal Patent Court also affirmed the validity of these patents, which solidifies the strength of many related patents. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241225151382/en/ Application Examples with CRI 70 or Higher (Photo: Seoul Semiconductor) These court orders relate to the core technology used to achieve CRI 70 (Color Rendering Index 70%) or higher, applicable to all home lighting, automotive lighting products, IT flash, and backlights. Since the effects of these judgments are applicable to all products infringing on the pa

ispace-EUROPE and the Italian Space Agency (ASI) Sign Payload Services Agreement to Transport a Laser Retroreflector Array (LaRA2) on the Moon Surface26.12.2024 08:00:00 CET | Press release

Agreement Marks Significant Step Towards Increasing Italy’s Contribution to advancing Lunar Exploration ispace EUROPE S.A. (ispace-EUROPE), the Luxembourg-based subsidiary of ispace, inc., and the Italian Space Agency (ASI) have signed a payload services agreement to transport a Laser Retroreflector Array (LaRA2) to enable accurate position measurements on the Moon via laser ranging experiments, the two organizations announced today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241225137548/en/ The shape of LaRA2, a palm-sized dome (Photo: Business Wire) The agreement marks the first full-scale contract between ispace-EUROPE and ASI, with both organizations looking to joint future lunar development. LaRA2 is a small, robust, and lightweight instrument built to work without any power source and to survive the harsh surface conditions on the Moon for an extended period of time. It features a precise array of retroreflectors

Datopotamab Deruxtecan Application in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer Voluntarily Withdrawn24.12.2024 08:00:00 CET | Press release

Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN) have voluntarily withdrawn the marketing authorization application (MAA) in the EU for datopotamab deruxtecan (Dato-DXd) for the treatment of adult patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) based on the TROPION-Lung01 phase 3 trial. The decision to withdraw the MAA was informed by feedback from the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA). Daiichi Sankyo and AstraZeneca will continue to work to bring datopotamab deruxtecan to patients with lung cancer in the EU who can benefit and are committed to unlocking the potential of this medicine in lung cancer through our robust clinical development program which includes seven pivotal trials in various lung cancer settings. Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed by Dai

Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 1323.12.2024 22:05:00 CET | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Dr. Reshma Kewalramani, Chief Executive Officer and President, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 10:30 a.m. ET/7:30 a.m. PT. A live webcast of management's remarks will be available through the Vertex website, www.vrtx.com in the "Investors" section under the "News and Events" page. A replay of the conference webcast will be archived on the company's website. About Vertex Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has approved medicines that treat the underlying causes of multiple chronic, life-shortening genetic diseases — cystic fibrosis, sickle cell disease and transfusion-dependent beta thalassemia — and continues to advance clinical and research programs in these diseases. Vertex also has a robust clinical pipeline of investigational

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye